Lonza executives outlined a roadmap to scale CAR‑T and specialized cell therapies through automation, global manufacturing networks, and early bioprocess development. Thomas Fellner, Lonza’s head of commercial development for specialized modalities, stressed the need to design manufacturable processes early to avoid costly failures during GMP scale‑up. Lonza framed automation, standardized platforms and distributed manufacturing as essential to meet rising demand as CAR‑T moves from last‑line to earlier treatment lines. The company highlighted capacity, supply chain coordination and quality systems as bottlenecks that automation can mitigate while protecting product consistency across sites. The strategy underscores how CDMOs and manufacturers must evolve to support personalized and allogeneic cell therapies at clinical and commercial scale.